We will further modify the CD19 CAR-UESC to obtain CD19 CAR-UiNK cells that ectopic production of IL-15, thereby enhancing their in vivo proliferation, persistence, and anti-tumor activity (6, 9, 65). The gene discussed is IL15; the disease is neoplasm.